http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 09:01:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Celularity+and+MuseCell+to+produce+cell+therapies+in+New+Jersey/26985929.html <p>Celularity Inc. (Nasdaq: CELU) and MuseCell Innovations® Pte. Ltd. announced a manufacturing collaboration under which Celularity will establish U.S. production of Dezawa MuseCells at its Florham Park, New Jersey facility.</p><p>The initial program is designed to build manufacturing capability for authenticated Dezawa MuseCell preparations derived from perinatal, bone marrow, and adipose starting materials, produced under the licensed Dezawa Method. The collaboration also covers DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome.</p><p>MuseCell Innovations projects that an expanded relationship could result in more than $300 million in aggregate purchases from Celularity over five years. The company stated this estimate reflects potential future programs http://www.streetinsider.com/Corporate+News/Celularity+and+MuseCell+to+produce+cell+therapies+in+New+Jersey/26985929.html Thu, 27 Aug 2026 09:01:16 -0400 CELU http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Press+Releases/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html <p class="bwalignc"> <i>Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®</i> </p> <p> FLORHAM PARK, N.J. &amp; SINGAPORE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelularity.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=Celularity+Inc.&amp;index=1&amp;md5=89054d5ec89560c3c494ec132016044d" shape="rect">Celularity Inc.</a> (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmusecellinnovations.com%2F&amp;esheet=54595257&amp;newsitemid=20260827982573&amp;lan=en-US&amp;anchor=MuseCell+Innovations%26%23174%3B&amp;index=2&amp;md5=f1b723aca0f94b9e02c1131c98220c42" shape="rect">MuseCell Innovations®</a> Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New http://www.streetinsider.com/Business+Wire/Celularity+and+MuseCell+Innovations%C2%AE+Announce+U.S.+Manufacturing+Collaboration+for+the+Dezawa+MuseCell%C2%AE+Platform/26985843.html Thu, 27 Aug 2026 09:00:00 -0400 A.50207248 CELU O.00386324 O.37572456 http://www.streetinsider.com/Corporate+News/Celularity+faces+Nasdaq+delisting+risk+over+missing+quarterly+filings/26976573.html <p>Celularity Inc. (NASDAQ: CELU) received a notification from Nasdaq's Listing Qualifications Department on August 21, 2026, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to missing quarterly financial filings.</p><p>The Florham Park, N.J.-based company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026, and remains delinquent in filing its Quarterly Report for the period ended March 31, 2026. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.</p><p>Nasdaq has requested that Celularity submit a plan to regain http://www.streetinsider.com/Corporate+News/Celularity+faces+Nasdaq+delisting+risk+over+missing+quarterly+filings/26976573.html Wed, 26 Aug 2026 05:40:01 -0400 CELU http://www.streetinsider.com/Press+Releases/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html <p align="justify">FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely http://www.streetinsider.com/Press+Releases/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html Tue, 25 Aug 2026 19:59:00 -0400 CELU CELU http://www.streetinsider.com/Press+Releases/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html <p align="justify">FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely http://www.streetinsider.com/Press+Releases/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html Tue, 25 Aug 2026 19:59:00 -0400 CELU CELU http://www.streetinsider.com/Globe+Newswire/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html <p align="justify">FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely http://www.streetinsider.com/Globe+Newswire/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html Tue, 25 Aug 2026 19:59:00 -0400 CELU CELU http://www.streetinsider.com/Globe+Newswire/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html <p align="justify">FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely http://www.streetinsider.com/Globe+Newswire/Celularity+Provides+Update+Regarding+Nasdaq+Listing+Compliance/26976088.html Tue, 25 Aug 2026 19:59:00 -0400 CELU CELU http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Celularity+Inc++++++++++++For%3A+Jun+30/26930304.html si-local-file:///var/storage/secattach/20260814/26930304.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Celularity+Inc++++++++++++For%3A+Jun+30/26930304.html Fri, 14 Aug 2026 16:10:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Celularity+Inc++++++++++++For%3A+Jun+30/26930304.html si-local-file:///var/storage/secattach/20260814/26930304.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Celularity+Inc++++++++++++For%3A+Jun+30/26930304.html Fri, 14 Aug 2026 16:10:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Aug+05/26892150.html si-local-file:///var/storage/secattach/20260807/26892150.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Aug+05/26892150.html Fri, 07 Aug 2026 17:11:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Aug+05/26892150.html si-local-file:///var/storage/secattach/20260807/26892150.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Aug+05/26892150.html Fri, 07 Aug 2026 17:11:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jul+23/26835250.html si-local-file:///var/storage/secattach/20260729/26835250.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jul+23/26835250.html Wed, 29 Jul 2026 16:15:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jul+23/26835250.html si-local-file:///var/storage/secattach/20260729/26835250.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jul+23/26835250.html Wed, 29 Jul 2026 16:15:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Celularity+Inc+++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26802037.html si-local-file:///var/storage/secattach/20260722/26802037.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Celularity+Inc+++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26802037.html Wed, 22 Jul 2026 16:25:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Celularity+Inc+++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26802037.html si-local-file:///var/storage/secattach/20260722/26802037.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Celularity+Inc+++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26802037.html Wed, 22 Jul 2026 16:25:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+26/26710653.html si-local-file:///var/storage/secattach/20260630/26710653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+26/26710653.html Tue, 30 Jun 2026 09:01:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+26/26710653.html si-local-file:///var/storage/secattach/20260630/26710653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+26/26710653.html Tue, 30 Jun 2026 09:01:00 -0400 CELU O.37572456 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+19/26693599.html si-local-file:///var/storage/secattach/20260625/26693599.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celularity+Inc++++++++++++For%3A+Jun+19/26693599.html Thu, 25 Jun 2026 17:27:00 -0400 CELU O.37572456